IOL Chemicals & Pharmaceuticals Ltd Q1 FY27 Earnings Analysis

- The company expects mid- to high-teen percentage revenue growth in FY 2027 and beyond. - Targeted top-line growth is around 15% annually on existing capacity. - Maximum revenue potential from existing capacity is estimated at INR 3,200 to 3,300 crores. - Capacity utilization for paracetamol expected to rise from 55% to 70-75% in FY 2027 and reach full capacity in FY 2028. - Ibuprofen business growth anticipated at 3%-4% annually with further export market expansion. - Non-ibuprofen exports expected to grow, with a target to reach about 25% export share in FY 2027. - New greenfield capex of INR 1,200 to 1,400 crores planned over 4-5 years, supporting gradual growth. - The company aims to maintain or improve EBITDA margins around 14%-14.5% alongside revenue growth.

- Company expects mid-teen to high-teen revenue growth for FY 2027 and over the medium term. - EBITDA margin guidance for FY 2027 is around 14% to 14.5%. - PAT growth anticipated in the range of 15% to 20%, maintaining previous guidance. - Capacity utilization improvements and operational efficiencies to support margin expansion. - Growth driven by higher contribution from non-Ibuprofen portfolio and increased exports, especially to Europe. - Capex of around INR 200-250 crores annually planned for the new greenfield site, with total outlay of INR 1,200-1,400 crores over 4-5 years to support scaled growth. - The company prefers to focus on yearly performance rather than quarterly, considering global market dynamism. Overall, steady growth with improved earnings and operating margins is expected, driven by operational efficiencies and product mix expansion.

- The company has acquired 100 acres of land near Bhatinda Highway for a new mega project. - Regulatory approvals are underway; environmental clearances are obtained. - The new project is expected to commence within 4 to 8 quarters (1 to 2 years). - The total capital outlay for this greenfield project is estimated between INR 1,200 to INR 1,400 crores. - Annual capex at the new site is planned around INR 200 to 250 crores, to be funded through internal accruals. - The overall capex will be phased and is expected to be completed over the next 4 to 5 years. - The new facility will likely follow a similar model to the existing plant, with a mix of chemical and API production. - For the current financial year (FY 2027), planned capex is approximately INR 200 crores focusing on growth, infrastructure, and efficiency improvements (60% growth-related, 40% infra/automation).

- No mention of any current or immediate plans for fundraising through debt or equity in the provided transcript. - The company is not considering a buyback currently, as the Board has not discussed it and focus remains on growth investments. - The company plans to fund its growth and capex requirements (including the new 100-acre land development) primarily through internal accruals. - Annual capex is expected to be around INR 200-250 crores, gradually phased over 4-5 years, with total capex for the greenfield project estimated between INR 1,200 to 1,400 crores. - Emphasis is on self-funded growth projects rather than raising capital externally at this stage.

The transcript provided does not explicitly mention the current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, relevant points related to company outlook and growth include: - The company is targeting around INR 2,700 crores in revenue for FY 2027, with mid-teen revenue growth expected annually. - Capacity utilization is high across key products (around 85%-95% for most products; paracetamol capacity utilization expected to rise from 55% to 75%). - Export share, especially for non-ibuprofen products, is expected to increase to around 25% in FY 2027. - The new greenfield project on 100 acres is planned with phased capex of INR 1,200 to 1,400 crores over 4 to 5 years to support future growth. - The company remains confident about maintaining momentum and growth over the next few quarters despite global uncertainties. No specific details about outstanding order book or pending orders are disclosed.